Nivalis Therapeutics
Boulder
About Nivalis Therapeutics
Nivalis Therapeutics is developing a novel class of disease-modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The Company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease-causing mutation in CF. Nivalis Therapeutics is dedicated to making a difference in the lives of patients with cystic fibrosis and their families. The company was founded in 2007 and is headquartered in Boulder, Colorado, United States.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $40.0M
- Funding stage: M&A
- Last round: Series Unknown (Nov 2014)
- Ticker: nasdaq:NVLS
- Website: nivalis.com
- Phone: 720-945-7700
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nivalis-therapeutics-1863039 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.